Keijo A. Väkiparta

UniCrop Oy develops sprouting technology for the production of therapeutic proteins. It develops prouting technology for the production of therapeutic proteins. It uses molecular biology technologies to develop new uses for plants. The company was founded by Kimmo Koivu and Viktor Kuvshinov in 1998 and is located in Helsinki, Finland.

Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. Genizon has one of the largest GWAS programs worldwide, addressing many common diseases and traits. Several of these have been successfully completed, generating comprehensive maps of interacting genes, biomarkers and biological disease pathways (known as GeneMaps), providing strong validation of the power of the Company's discovery platform. Genizon has out-licensed some of the therapeutic and diagnostic rights to GeneMaps for Crohn's disease (to Genentech) and attention deficit hyperactivity disorder, endometriosis and Alzheimer's disease (disease-state diagnostic rights to Pfizer). GeneMaps have also been generated from GWAS in schizophrenia, psoriasis and longevity. GWAS are in progress for rheumatoid arthritis, Alzheimer's disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension (collectively metabolic syndrome). Genizon's technology platform and discoveries can complement current R&D programs by using human genetics to significantly enhance research and by adding value at multiple stages of the drug development process. Genizon is continually developing and enhancing its gene and biomarker discovery platform. For example, the company is assessing the role of copy number variations (CNVs) in diseases- applying new methods to ongoing large-scale GWAS in rheumatoid arthritis and metabolic syndrome, and retrospectively to previous studies. Genizon also leverages its platform and expertise by offering high throughput, high quality SNP genotyping, statistical genetics, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry.

Ipsat Therapies Oy develops and manufactures antibiotics & drugs. Its products include penicillins, cephalosporins and carbapenems. The firm develops products for the prevention of antibiotic resistance, antibiotic-associated diarrhea and hospital associated infections. The company was founded in 2000 and is headquartered in Helsinki, Finland.

Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden.

Juvantia Pharma Oy discovers and develops pharmaceuticals and drugs. The firm develops products for the treatment of Parkinson's disease, depression and schizophrenia, vasoconstrictive disorders, fibro proliferative vasculopathies and chronic pain.The company was founded by Risto Arvo Sakari Lammintausta in 1997 and is headquartered in Turku, Finland.